Literature DB >> 18614644

Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.

Maryam Ahmed1, Tracie R Marino, Shelby Puckett, Nancy D Kock, Douglas S Lyles.   

Abstract

Matrix (M) protein mutants of vesicular stomatitis virus (VSV), such as rM51R-M virus, are less virulent than wild-type (wt) VSV strains due to their inability to suppress innate immunity. Studies presented here show that when inoculated intranasally into mice, rM51R-M virus was cleared from nasal mucosa by day 2 postinfection and was attenuated for spread to the central nervous system, in contrast to wt VSV, thus accounting for its reduced virulence. However, it stimulated an antibody response similar to that in mice infected with the wt virus, indicating that it has the ability to induce adaptive immunity in vivo without causing disease. These results support the use of M protein mutants of VSV as vaccine vectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614644      PMCID: PMC2546904          DOI: 10.1128/JVI.00915-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development.

Authors:  E B Flanagan; J M Zamparo; L A Ball; L L Rodriguez; G W Wertz
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis.

Authors:  Maryam Ahmed; Margie O McKenzie; Shelby Puckett; Michael Hojnacki; Laurent Poliquin; Douglas S Lyles
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice.

Authors:  B S Huneycutt; Z Bi; C J Aoki; C S Reiss
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis.

Authors:  B S Huneycutt; I V Plakhov; Z Shusterman; S M Bartido; A Huang; C S Reiss; C Aoki
Journal:  Brain Res       Date:  1994-01-28       Impact factor: 3.252

7.  Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins.

Authors:  Jean-Francois Valarcher; Julie Furze; Sara Wyld; Roy Cook; Karl-Klaus Conzelmann; Geraldine Taylor
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.

Authors:  Anjeanette Roberts; Jon D Reuter; Jean H Wilson; Stuart Baldwin; John K Rose
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  29 in total

1.  Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Authors:  M Ahmed; S Puckett; D S Lyles
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

Review 2.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

3.  Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.

Authors:  Gyoung Nyoun Kim; Kunyu Wu; Jiho Patrick Hong; Zain Awamleh; C Yong Kang
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

4.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Authors:  Maryam Ahmed; Latoya M Mitchell; Shelby Puckett; Kristina L Brzoza-Lewis; Douglas S Lyles; Elizabeth M Hiltbold
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

6.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Authors:  Megan Moerdyk-Schauwecker; Nirav R Shah; Andrea M Murphy; Eric Hastie; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  Virology       Date:  2012-12-14       Impact factor: 3.616

8.  Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Authors:  Yuanmei Ma; Yue Duan; Yongwei Wei; Xueya Liang; Stefan Niewiesk; Michael Oglesbee; Jianrong Li
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.

Authors:  Xin Zhao; Shengsong Huang; Huarong Luo; Xiaodong Wan; Yaping Gui; Junliang Li; Denglong Wu
Journal:  Int J Clin Exp Med       Date:  2014-05-15

10.  Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.

Authors:  Jason R Smedberg; Marlena M Westcott; Maryam Ahmed; Douglas S Lyles
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.